G Barbaro

Summary

Country: Italy

Publications

  1. ncbi Human immunodeficiency virus & cardiovascular risk
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Indian J Med Res 134:898-903. 2011
  2. ncbi Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
    Fabrizio Mecenate
    Liver Unit San Camillo Forlanini Hospital, Rome, Italy
    BMC Gastroenterol 10:21. 2010
  3. ncbi Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University of Rome La Sapienza, Rome, Italy
    Chemotherapy 52:161-5. 2006
  4. ncbi An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Clin Ther 25:2405-18. 2003
  5. ncbi Guidelines for the prevention and management of cardiovascular complications in HIV-infected patients receiving HAART: The Pavia Consensus Statement
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:226-32. 2003
  6. ncbi Vasculitic syndromes in HIV-infected patients
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:185-96. 2003
  7. ncbi HIV-associated lipodystrophy: pathogenesis and clinical features
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:97-104. 2003
  8. ncbi Pathogenesis of HIV-associated cardiovascular disease
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:49-70. 2003
  9. ncbi Evolution of the involvement of the cardiovascular system in HIV infection
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:15-22. 2003
  10. ncbi Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Pharmacology 69:177-9. 2003

Collaborators

Detail Information

Publications69

  1. ncbi Human immunodeficiency virus & cardiovascular risk
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Indian J Med Res 134:898-903. 2011
    ....
  2. ncbi Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
    Fabrizio Mecenate
    Liver Unit San Camillo Forlanini Hospital, Rome, Italy
    BMC Gastroenterol 10:21. 2010
    ..The aim of this study was to compare the efficacy of 12 or 24 weeks of treatment in patients with chronic HCV genotype 2 or 3 and to identify patients suitable for 12 weeks treatment...
  3. ncbi Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University of Rome La Sapienza, Rome, Italy
    Chemotherapy 52:161-5. 2006
    ..A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines...
  4. ncbi An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Clin Ther 25:2405-18. 2003
    ....
  5. ncbi Guidelines for the prevention and management of cardiovascular complications in HIV-infected patients receiving HAART: The Pavia Consensus Statement
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:226-32. 2003
  6. ncbi Vasculitic syndromes in HIV-infected patients
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:185-96. 2003
  7. ncbi HIV-associated lipodystrophy: pathogenesis and clinical features
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:97-104. 2003
  8. ncbi Pathogenesis of HIV-associated cardiovascular disease
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:49-70. 2003
  9. ncbi Evolution of the involvement of the cardiovascular system in HIV infection
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:15-22. 2003
  10. ncbi Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Pharmacology 69:177-9. 2003
    ..All HIV-infected patients are candidates for antiretroviral therapy and patients already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk according to the available guidelines...
  11. ncbi Takotsubo-like left ventricular dysfunction in an HIV-infected patient
    Giuseppe Barbaro
    Cardiology Unit, Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Curr HIV Res 4:239-41. 2006
    ..We report a case of takotsubo-like left ventricular dysfunction in an human immunodeficiency virus (HIV)-infected caucasian patient...
  12. ncbi Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome
    Giuseppe Barbaro
    Cardiology Unit, Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Curr Pharm Des 13:2208-13. 2007
    ....
  13. ncbi HIV infection and cancer in the era of highly active antiretroviral therapy (Review)
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, 00174 Rome, Italy
    Oncol Rep 17:1121-6. 2007
    ..A better knowledge of viral mechanisms of immune evasion and manipulation will provide the basis for a better management and treatment of the malignancies associated with chronic viral infections...
  14. ncbi HIV-associated myocarditis
    Giuseppe Barbaro
    La Sapienza University of Rome, Rome, Italy
    Heart Fail Clin 1:439-48. 2005
  15. ncbi Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy
    G Barbaro
    Viale Anicio Gallo 63, 00174 Rome, Italy
    Curr Drug Targets Cardiovasc Haematol Disord 5:337-43. 2005
    ..A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART according to the most recent clinical guidelines is needed...
  16. ncbi HIV-associated cardiomyopathy etiopathogenesis and clinical aspects
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University of Rome La Sapienza, Rome, Italy
    Herz 30:486-92. 2005
    ..Data on the role of HAART in the treatment of HIVassociated myocarditis and cardiomyopathy are lacking...
  17. ncbi Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University of Rome La Sapienza, Rome, Italy
    Am J Ther 13:248-60. 2006
    ..A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines...
  18. ncbi Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Curr HIV Res 4:79-85. 2006
    ..A careful stratification of the cardiovascular risk of HIV-infected patients under HAART is needed according to the most recent clinical guidelines...
  19. ncbi HIV infection, highly active antiretroviral therapy and the cardiovascular system
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Cardiovasc Res 60:87-95. 2003
    ..All HIV-infected patients candidate to antiretroviral therapy and patients already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk with the available guidelines...
  20. ncbi Cardiovascular manifestations of HIV infection
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Circulation 106:1420-5. 2002
  21. ncbi Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study
    Giuseppe Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    Eur J Gastroenterol Hepatol 14:477-83. 2002
    ..To evaluate the long-term efficacy of consensus interferon in the treatment of chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, combination therapy with interferon alpha-2b and ribavirin...
  22. ncbi HIV infection and the cardiovascular system
    Giuseppe Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    AIDS Rev 4:93-103. 2002
    ..In addition, the study of HIV-related cardiovascular disease may shed light on the mechanisms of non-HIV-related cardiovascular disease...
  23. ncbi Pathogenesis of HIV-associated cardiomyopathy
    G Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    Ann N Y Acad Sci 946:57-81. 2001
    ..In this review article we discuss HIV-associated cardiovascular complications, focusing on pathogenetic mechanisms that may play a role in diagnosis, management, and therapy of these complications...
  24. ncbi HIV-associated cardiovascular complications: a new challenge for emergency physicians
    G Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    Am J Emerg Med 19:566-74. 2001
    ..In this review article, we will discuss HIV-associated cardiac disease which may be encountered in the ED, emphasizing the prevalence, pathogenesis, and treatment of related disorders...
  25. ncbi HIV infection, antiretroviral therapy and cardiovascular risk
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    J Cardiovasc Risk 9:295-300. 2002
    ..All HIV-infected patients candidate to antiretroviral therapy and patients already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk with the available guidelines...
  26. ncbi Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial
    G Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    J Hepatol 35:406-11. 2001
    ..To evaluate the therapeutic efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B...
  27. ncbi Pathogenesis of HIV-associated heart disease
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    AIDS 17:S12-20. 2003
    ....
  28. ncbi Cardiovascular complications in the acquired immunodeficiency syndrome
    Giuseppe Barbaro
    Departamento de Fisiopatologia Médica, Policlínica Umberto Primo, Universidade La Sapienza, Roma, Italia
    Rev Assoc Med Bras 55:621-30. 2009
    ..A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce cardiovascular risk in HIV-infected patients receiving HAART...
  29. ncbi Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Curr Pharm Des 9:1475-81. 2003
    ....
  30. ncbi Metabolic syndrome associated with HIV and highly active antiretroviral therapy
    Giuseppe Barbaro
    Cardiology Unit, Department of Medical Pathophysiology, University La Sapienza, Viale Anicio Gallo 63, 00174 Rome, Italy
    Curr Diab Rep 9:37-42. 2009
    ....
  31. ncbi Interactions between antiretroviral agents and drugs commonly used to treat cardiovascular diseases according to the Pavia Consensus Statement
    Giuseppe Barbaro
    Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Adv Cardiol 40:233-40. 2003
  32. ncbi Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection
    G Barbaro
    Cardiology Unit, Department of Medical Pathophysiology, University La Sapienza, Rome, Italy
    Clin Ter 159:51-5. 2008
    ..A careful cardiovascular screening and monitoring of HIV-infected patients receiving HAART is needed according to the most recent clinical guidelines...
  33. ncbi Pathogenesis of HIV-associated cardiovascular complications
    G Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    Lancet Infect Dis 1:115-24. 2001
    ..In this review we discuss HIV-associated cardiovascular complications focusing on pathogenetic mechanisms that could have a role in diagnosis, management, and therapy of these complications in the HAART era...
  34. ncbi Management of chronic hepatitis in drug addicts: a systematic review
    A M Pellicelli
    Liver Unit San Camillo Forlanini Hospital, Rome, Italy
    Clin Ter 159:41-9. 2008
    ..In this review we describe the epidemiology, diagnosis and treatment of chronic hepatitis C, B and Delta in intravenous drug users...
  35. ncbi Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents
    Massimo Fantoni
    Department of Infectious Diseases, Catholic University, Rome, Italy
    Ital Heart J 3:294-9. 2002
    ..It is likely that the metabolic disorders related to anti-HIV treatment will eventually translate into an increased cardiovascular risk in patients submitted to such regimens...
  36. ncbi Primary pulmonary hypertension in HIV patients: a systematic review
    A M Pellicelli
    Second Division of Infectious Diseases, IRCCS Lazzaro Spallanzani Hospital, Rome, Italy
    Angiology 52:31-41. 2001
    ..High levels of cytokines present in AIDS patients can favor pulmonary hypertension, but the role of a host response to HIV--determined by one or more HLA subtypes--is suspected to enhance high cytokine production levels...
  37. ncbi Threshold values of high-risk echocardiographic epicardial fat thickness
    Gianluca Iacobellis
    Department of Medicine, Cardiovascular Obesity Research and Management, McMaster University, Hamilton, Ontario, Canada
    Obesity (Silver Spring) 16:887-92. 2008
    ..In this study, we sought to provide threshold values of echocardiographic epicardial fat thickness associated with metabolic and anthropometric risk factors...
  38. ncbi Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat
    Gianluca Iacobellis
    Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Obesity (Silver Spring) 16:179-83. 2008
    ..However, the potential link between cardiac adiposity, emerging index of visceral adiposity, and fatty liver is still unexplored...
  39. ncbi Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study
    Giuseppe Barbaro
    Department of Emergency Medicine, University La Sapienza, Rome, Italy
    BioDrugs 17:433-9. 2003
    ....
  40. ncbi Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation
    Adriano M Pellicelli
    Liver Unit, Azienda Ospedaliera San Camillo, Forlanini, Rome, Italy
    Angiology 61:802-6. 2010
    ..Endothelin 1 and IL-6 could be implicated in the pathogenesis of PPHTN. On the basis of these results, ET-1 receptor antagonists or anti-IL-6 could have a rationale in the treatment of PPHTN...
  41. ncbi Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study
    Adriano M Pellicelli
    Liver Unit San Camillo Forlanini Hospital, Rome, Italy
    Clin Ther 30:317-23. 2008
    ..Furthermore, we evaluated in these selected patients the clinical co-variates associated with a sustained virologic response...
  42. ncbi Cardiac metabolism in myocardial ischemia
    Giuseppe M C Rosano
    IRCCS San Raffaele, Centre for Clinical and Basic Research, Department of Medical Sciences, via della Pisana 235, 00166, Rome, Italy
    Curr Pharm Des 14:2551-62. 2008
    ..The paper will review the alterations in energy metabolism that occur during acute and chronic ischemia...
  43. ncbi Chronic sildenafil in men with diabetes and erectile dysfunction
    Antonio Aversa
    University of Rome La Sapienza, Dept of Medical Pathophysiology, Viale Policlinico 155 00161 Rome, Italy
    Expert Opin Drug Metab Toxicol 3:451-64. 2007
    ..If this approach proves successful, it will determine many advantages over the intracavernosal treatment and potentially induce sexual rehabilitation...
  44. ncbi Cardiovascular monitoring of HIV-infected patients
    Giuseppe Barbaro
    J Cardiovasc Med (Hagerstown) 7:379; author reply 380. 2006
  45. ncbi Long-term effects of protease-inhibitor-based combination therapy
    Giuseppe Barbaro
    Lancet 363:900; author reply 900-1. 2004
  46. ncbi Adiponectin and HIV associated lipodystrophy
    Giuseppe Barbaro
    Med Sci Monit 9:LE26. 2003
  47. ncbi The pavia consensus statement
    Paul A Volberding
    University of California, San Francisco, USA
    AIDS 17:S170-9. 2003
  48. ncbi HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis
    Milan Fiala
    Department of Medicine, Greater Los Angeles VA Medical Center, Los Angeles, CA, USA
    Cardiovasc Toxicol 4:327-37. 2004
    ..In conclusion, HIV-1 and gp120 induce toxicity through induction of cardiomyocyte and endothelial cell apoptosis. HAART drugs disrupt endothelial cell junctions and mitochondria and could cause vascular damage...
  49. ncbi Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients
    Raymond M Johnson
    Division of Infectious Diseases, Indiana School of Medicine, Indianapolis, Indiana 46202, USA
    AIDS 17:S77-82. 2003
    ..Immunohistopathology of the affected arteries suggests that he died of a Kawasaki-like syndrome...
  50. ncbi Incidence of the involvement of the cardiovascular system in HIV infection
    Giorgio Barbarinia
    Department of Infectious and Tropical Diseases, Policlinico S. Matteo, University of Pavia, Italy
    AIDS 17:S46-50. 2003
    ....
  51. ncbi Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy
    Robert L Murphy
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois, USA
    AIDS 17:S1-3. 2003
  52. ncbi Increased access to the emergency department for coronary heart disease of HIV-infected patients receiving highly active antiretroviral therapy
    Giuseppe Barbaro
    Ann Emerg Med 40:530-1. 2002
  53. ncbi Protease inhibitors and mortality among children and adolescents infected with HIV-1
    Giuseppe Barbaro
    N Engl J Med 346:1026-7; author reply 1026-7. 2002
  54. ncbi Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors
    Antonio Mastrolorenzo
    Universita degli Studi di Firenze, Dipartimento di Chimica, Laboratorio di Chimica Bioinorganica, I 50019 Sesto Fiorentino, Florence, Italy
    Curr Med Chem 14:2734-48. 2007
    ....
  55. ncbi Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda
    Marc Twagirumukiza
    Internal Medicine Department, Cardiovascular Clinical Pharmacology, University Hospital CHU of Butare, Rwanda
    Curr HIV Res 5:129-37. 2007
    ..However, factors associated with the development of HIV-associated cardiomyopathy in developing countries are still debated...
  56. ncbi Regarding: Right ventricular cardiac dysfunction in HIV-infected patients studied with radionuclide ventriculography
    Giuseppe Barbaro
    Am Heart J 148:e18. 2004
  57. ncbi Reversible right ventricular dysfunction in HIV-infected patients
    Giuseppe Barbaro
    South Med J 99:197. 2006
  58. ncbi Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus
    Gianluca Iacobellis
    Cardiovascular Obesity Research and Management at the Michael G deGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Cardiol 99:1470-2. 2007
    ..81, p <0.01). In conclusion, this study suggests, for the first time, that epicardial adipose tissue, an index of cardiac adiposity, may be significantly related to subclinical atherosclerosis in HIV-infected patients...
  59. ncbi Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome
    Giuseppe Barbaro
    Universita degli Studi di Firenze, Dipartimento di Chimica, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, Rm 188, I 50019 Sesto Fiorentino, Florence, Italy
    Curr Pharm Des 11:1805-43. 2005
    ....
  60. ncbi Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome
    Gianluca Iacobellis
    Cardiovascular Obesity Research and Management at the Michael G deGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr HIV Res 5:275-9. 2007
    ..Detection of epicardial fat thickness, new index of visceral adiposity in non HIV-infected patients, might be important as diagnostic tool in HIV-infected patients on HAART...
  61. ncbi [Cardiovascular manifestations in patients infected with the human immunodeficiency virus]
    Ludhmila Abrahao Hajjar
    Instituto do Coracao, Hospital das Clinicas, FMUSP, Sao Paulo, SP
    Arq Bras Cardiol 85:363-77. 2005
  62. ncbi Elegant study performed to assess the early impaired autonomic function in HIV-infected subjects
    Giuseppe Barbaro
    Pacing Clin Electrophysiol 29:803; author reply 803-4. 2006
  63. ncbi Selenium deficiency and HIV-associated cardiomyopathy
    Giuseppe Barbaro
    J R Soc Med 95:57. 2002
  64. ncbi HIV-associated cardiomyopathy is not Keshan disease
    Giuseppe Barbaro
    J R Soc Med 95:324. 2002
  65. ncbi Contrast echocardiography of right atrial mass due to hepatocellular carcinoma
    Adriano M Pellicelli
    Department of Internal Medicine, Liver Unit, San Camillo Forlanini Hospital, Italy
    Acta Cardiol 61:471-3. 2006
    ....
  66. ncbi Methadone and QT prolongation in HIV-infected patients
    Alfio Lucchini
    Am J Cardiol 94:147-8. 2004
  67. ncbi Clinical findings of Takotsubo cardiomyopathy: results from a multicenter international study
    Giovanni Fazio
    Department of Cardiology, University of Palermo, Italy
    J Cardiovasc Med (Hagerstown) 9:239-44. 2008
    ..To date, many reports concerning this kind of acute reversible heart failure have been published, but the information available about the management of affected patients is scarce and the clinical data are incomplete...
  68. ncbi Chronic pharmacological treatment in takotsubo cardiomyopathy
    Giovanni Fazio
    Int J Cardiol 127:121-3. 2008
    ..Thus, it seem to be important an early correct differential diagnosis to avoid any chronic treatment in these patients...
  69. ncbi Pharmacological therapy in children with atrial fibrillation and atrial flutter
    Giovanni Fazio
    Department of Cardiology, University of Palermo, Italy
    Curr Pharm Des 14:770-5. 2008
    ..In this review we evaluated the physiopathology, the clinical features and the current terapeutical strategies for these arrythmias in paediatric age...